Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
Sci Rep
.
2023 Mar 3;13(1):3620.
doi: 10.1038/s41598-023-30374-9.
Authors
Niki Karachaliou
1
,
Jordi Codony-Servat
2
,
Cristina Teixidó
2
,
Sara Pilotto
3
,
Ana Drozdowskyj
4
,
Carles Codony-Servat
2
,
Ana Giménez-Capitán
2
,
Miguel Angel Molina-Vila
2
,
Jordi Bertrán-Alamillo
2
,
Radj Gervais
5
,
Bartomeu Massuti
6
,
Teresa Morán
7
,
Margarita Majem
8
,
Enriqueta Felip
9
,
Enric Carcereny
7
,
Rosario García-Campelo
10
,
Santiago Viteri
1
,
María González-Cao
1
,
Daniela Morales-Espinosa
1
,
Alberto Verlicchi
11
,
Elisabetta Crisetti
12
,
Imane Chaib
7
,
Mariacarmela Santarpia
13
,
José Luis Ramírez
7
,
Joaquim Bosch-Barrera
14
,
Andrés Felipe Cardona
15
,
Filippo de Marinis
16
,
Guillermo López-Vivanco
17
,
José Miguel Sánchez
18
,
Alain Vergnenegre
19
,
José Javier Sánchez Hernández
20
,
Isabella Sperduti
21
,
Emilio Bria
3
,
Rafael Rosell
22
23
24
25
26
Affiliations
1
Instituto Oncológico Dr Rosell, Quiron-Dexeus University Hospital, Barcelona, Spain.
2
Pangaea Biotech, Barcelona, Spain.
3
Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
4
Pivotal, Madrid, Spain.
5
Centre François Baclesse, Caen, France.
6
Hospital General de Alicante, Alicante, Spain.
7
Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.
8
Hospital de Sant Pau, Barcelona, Spain.
9
Hospital Vall d'Hebron, Barcelona, Spain.
10
Complexo Hospitalario Universitario La Coruña, La Coruña, Spain.
11
Ospedale Santa Maria delle Croci, Ravenna, Italy.
12
Department of Medical and Surgical Sciences, Institute of Respiratory Diseases, University of Foggia, Foggia, Italy.
13
Human Pathology Department, Medical Oncology Unit, University of Messina, Messina, Italy.
14
Catalan Institute of Oncology, Hospital Josep Trueta, Girona, Spain.
15
Clinical and Traslational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia.
16
Divisione di Oncologica Toracica, Direttore, Istituto Europeo di Oncologia-IEO, Milano, Italy.
17
Chief, Medical Oncology Service, Hospital de Cruces, Barakaldo, Vizcaya, Spain.
18
Medical Oncology Service, Hospital de la Princesa, Madrid, Spain.
19
Hôpital du Cluzeau, Limoges, France.
20
Unidad de Investigación en Salud Pública CIDICS-UANL, Monterrey, Mexico.
21
Biostatistics, Regina Elena National Cancer Institute, Rome, Italy.
22
Instituto Oncológico Dr Rosell, Quiron-Dexeus University Hospital, Barcelona, Spain. rrosell@iconcologia.net.
23
Pangaea Biotech, Barcelona, Spain. rrosell@iconcologia.net.
24
Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain. rrosell@iconcologia.net.
25
Molecular Oncology Research (MORe) Foundation, Barcelona, Spain. rrosell@iconcologia.net.
26
Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Barcelona, Spain. rrosell@iconcologia.net.
PMID:
36869103
PMCID:
PMC9984426
DOI:
10.1038/s41598-023-30374-9
No abstract available
Publication types
Published Erratum